AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29975565 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (walking, 60%-70% of max HR) at -15°C
Number of subjects: 16
Study 29975565 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (walking, 60%-70% of max HR) at +22°C
Number of subjects: 16
Study 29975565 — intervention group
Group type: COMPARATOR
Intervention: Seated rest at +22°C
Number of subjects: 16
Study 29975565 — intervention group
Group type: COMPARATOR
Intervention: Seated rest at -15°C
Number of subjects: 16
Study 29975565 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the cold
Number of subjects: 16
Study 26559450 — intervention group
Group type: EXPERIMENTAL
Intervention: 15RM Resistance Exercise
Number of subjects: 15
Study 26559450 — intervention group
Group type: COMPARATOR
Intervention: 4RM Resistance Exercise
Number of subjects: 15
Study 23602304 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeSlips creative storytelling program (two one-hour sessions per week for six weeks)
Number of subjects: 20
Study 23602304 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care activity programming (control group)
Number of subjects: 20
Study 22082250 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplug-delivered sleep-inducing music for 52 min beginning at 10:00 pm, while wearing an eyeshield, n = 29
Number of subjects: 58
Study 22082250 — intervention group
Group type: COMPARATOR
Intervention: No music, but earplugs and eyeshield worn, n = 29
Number of subjects: 58
Study 20643703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (8-week computerized program)
Number of subjects: 24
Study 17463460 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug intervention to prevent diabetes (specific drug not mentioned)
Number of subjects: 0
Study 15045169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sedation level (Bloomsbury Sedation Score) and higher degree of consciousness (Glasgow Coma Scale)
Number of subjects: 74
Study 15045169 — intervention group
Group type: COMPARATOR
Intervention: Surgical ICUs
Number of subjects: 74
Study 15045169 — intervention group
Group type: COMPARATOR
Intervention: Medical ICU/CCUs
Number of subjects: 74
Study 15045169 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment tool based on identified risk factors
Number of subjects: 74
Study 15045169 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic administration of the Bloomsbury Sedation Score and the Glasgow Coma Scale
Number of subjects: 74
Study 15045169 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of sedative drugs during weaning, timely extubation, increased surveillance
Number of subjects: 74
Study 12194393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 0.5 mg neostigmine
Number of subjects: 105
Study 12194393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 2% lidocaine
Number of subjects: 105
Study 12194393 — intervention group
Group type: COMPARATOR
Intervention: 1 ml normal saline
Number of subjects: 105
Study 9793813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms, 37.5 micrograms, 50 micrograms)
Number of subjects: 60
Study 9793813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 micrograms, 10 micrograms, 15 micrograms)
Number of subjects: 60
Study 9793813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl and sufentanil
Number of subjects: 60
Study 9793813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 60
Study 8602376 — intervention group
Group type: COMPARATOR
Intervention: zidovudine 600 mg/day alone
Number of subjects: 6
Study 8602376 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine with cimetidine 1200 mg/day
Number of subjects: 6
Study 8602376 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine with ranitidine 300 mg/day
Number of subjects: 6
Study 2628637 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held weights (2.27 kg) during running
Number of subjects: 10
Study 2628637 — intervention group
Group type: COMPARATOR
Intervention: Hand-held weights (0, 0.45, 1.36 kg) during walking
Number of subjects: 10
Study 2628637 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held weights (2.27 kg or less) during walking
Number of subjects: 10
Study 319269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine sulfate and theophylline combination
Number of subjects: 16
Study 31325161 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous somatostatin (22 µg/kg)
Number of subjects: 6
Study 31325161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin (22 µg/kg)
Number of subjects: 6
Study 27873023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (AC) 3 × 100 mg for 3 weeks
Number of subjects: 90
Study 27873023 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) body weight adjusted dose for 3 days
Number of subjects: 90
Study 27873023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Acetylcysteine and Azithromycin at described doses
Number of subjects: 90
Study 26415992 — intervention group
Group type: EXPERIMENTAL
Intervention: nintedanib+docetaxel
Number of subjects: 1307
Study 23535165 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) added to optimal medical management
Number of subjects: 1200
Study 23535165 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management alone (control group)
Number of subjects: 1200
Study 21818634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (Group II)
Number of subjects: 72
Study 21818634 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (Group I)
Number of subjects: 72
Study 21818634 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional status (Group III)
Number of subjects: 72
Study 18071727 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin alone
Number of subjects: 170
Study 18071727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (prednisone, aspirin, progesterone)
Number of subjects: 170
Study 18071727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18071727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment vs Enoxaparin
Number of subjects: 170
Study 18071727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups (Enoxaparin and Combination)
Number of subjects: 170
Study 16507072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile hydroalcoholic extract
Number of subjects: 40
Study 16507072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 40
Study 16507072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 40
Study 16507072 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 40
Study 16507072 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl + 17% EDTA (positive control)
Number of subjects: 40
Study 15047684 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 14
Study 15047684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese diet
Number of subjects: 14
Study 15047684 — intervention group
Group type: COMPARATOR
Intervention: Milk diet
Number of subjects: 14
Study 10767224 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold loading test (inspiratory and expiratory)
Number of subjects: 36
Study 10767224 — intervention group
Group type: COMPARATOR
Intervention: Histamine bronchial provocation test
Number of subjects: 36
Study 9075507 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 300 mg alone
Number of subjects: 56
Study 9075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 300 mg with fentanyl 100 micrograms
Number of subjects: 56
Study 9075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 200 mg with fentanyl 100 micrograms
Number of subjects: 56
Study 9075507 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 56
Study 7924831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (cocktail of several antioxidants at high dosage)
Number of subjects: 0
Study 7924831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte photopheresis (treatment of lymphocytes with methoxypsoralen and UVA irradiation)
Number of subjects: 0
Study 7924831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for lymphocyte photopheresis)
Number of subjects: 0
Study 3555054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily for seven days)
Number of subjects: 225
Study 3555054 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for seven days)
Number of subjects: 225
Study 3555054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 225
Study 3555054 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 225
Study 28189366 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP002A (oral formulation of Δ9-tetrahydrocannabinol)
Number of subjects: 24
Study 27942550 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day as an intravenous bolus once daily for 3 days before and 3 days after chemotherapy)
Number of subjects: 90
Study 27942550 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (once daily for 3 days before and 3 days after chemotherapy)
Number of subjects: 90
Study 24148140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed to link those with SUDs to treatment
Number of subjects: 1441
Study 22578757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertubation with lidocaine
Number of subjects: 26
Study 20233982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and tailored telephone follow-up after discharge
Number of subjects: 862
Study 20233982 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 862
Study 18397986 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 60
Study 18397986 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU) treatment
Number of subjects: 60
Study 16816308 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment (n = 75)
Number of subjects: 150
Study 16816308 — intervention group
Group type: COMPARATOR
Intervention: Traditional vocational services (n = 75)
Number of subjects: 150
Study 14671225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 11004361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus amnioinfusion (500 mL over 30 minutes, repeated if necessary)
Number of subjects: 65
Study 11004361 — intervention group
Group type: COMPARATOR
Intervention: Continuous amnioinfusion (500 mL over 30 minutes, then 3 mL per minute until delivery)
Number of subjects: 65
Study 11004361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intermittent and continuous amnioinfusion)
Number of subjects: 65
Study 8644646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 54
Study 8644646 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 54
Study 8644646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1350596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 207
Study 1350596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and beta-blocker combination
Number of subjects: 207
Study 6364879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg oral administration)
Number of subjects: 7
Study 6364879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30016193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, 600 J in two phases and 15 J to 10 points for a total of 750 J for each knee, thrice per week for 4 weeks.
Number of subjects: 30
Study 30016193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, thrice per week for 4 weeks.
Number of subjects: 30
Study 30016193 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser with exercise program, same frequency and duration as the intervention group.
Number of subjects: 30
Study 27959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (mean daily dose: 209±37 mg)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (mean daily dose: 852±103 mg)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (mean daily dose: 2045±246 mg)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (on-treatment analysis)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (on-treatment analysis)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (on-treatment analysis)
Number of subjects: 24081
Study 27959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24081
Study 24343476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (3.22 mg/day)
Number of subjects: 60
Study 24343476 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0.6 mg/day)
Number of subjects: 60
Study 22499474 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly EBP-structured case conference (Group A)
Number of subjects: 94
Study 22499474 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture about EBP (Group B)
Number of subjects: 94
Study 19713265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 0
Study 19713265 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (50 microg/kg) plus glycopyrrolate (10 microg/kg)
Number of subjects: 0
Study 18846435 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 225
Study 18846435 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LA)
Number of subjects: 225
Study 18846435 — intervention group
Group type: COMPARATOR
Intervention: Combined analysis of DMPA and LA
Number of subjects: 225
Study 16126582 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated data acquisition package of 12 lead ECG signals; QRS complex detector with accuracy level approximately 98.4%
Number of subjects: 0
Study 16126582 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-plane analysis using Discrete Fourier Transform (DFT)
Number of subjects: 0
Study 16126582 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of amplitude property
Number of subjects: 0
Study 12092742 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 24
Study 12092742 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 24
Study 10643545 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg for seven opioid-naïve patients and 3.75 mg for two patients on top of their regular oral dose of 7.5 mg q4 h)
Number of subjects: 9
Study 10643545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10643545 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 9
Study 7768345 — intervention group
Group type: COMPARATOR
Intervention: Normal surface, eyes open
Number of subjects: 0
Study 7768345 — intervention group
Group type: COMPARATOR
Intervention: Normal surface, eyes closed
Number of subjects: 0
Study 7768345 — intervention group
Group type: COMPARATOR
Intervention: Foam surface, eyes open
Number of subjects: 0
Study 7768345 — intervention group
Group type: COMPARATOR
Intervention: Foam surface, eyes closed
Number of subjects: 0
Study 7768345 — intervention group
Group type: EXPERIMENTAL
Intervention: Total power calculated between 0 and 4Hz
Number of subjects: 0
Study 7768345 — intervention group
Group type: EXPERIMENTAL
Intervention: Slopes of logarithmically transformed data
Number of subjects: 0
Study 2190436 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (Ridaura)
Number of subjects: 0
Study 6107406 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin
Number of subjects: 9
Study 6107406 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 9
Study 30269650 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning programme
Number of subjects: 97
Study 30269650 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 27876200 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program (intervention group)
Number of subjects: 10861
Study 27876200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10861
Study 26021226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucositis (M)
Number of subjects: 75
Study 26021226 — intervention group
Group type: COMPARATOR
Intervention: Peri-implantitis (P)
Number of subjects: 75
Study 26021226 — intervention group
Group type: COMPARATOR
Intervention: Healthy (H)
Number of subjects: 75
Study 23564915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg
Number of subjects: 446
Study 23564915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 21332799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) supplementation
Number of subjects: 145
Study 21332799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 19125875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + intravenous metoclopramide + diphenhydramine
Number of subjects: 182
Study 19125875 — intervention group
Group type: COMPARATOR
Intervention: Placebo + intravenous metoclopramide + diphenhydramine
Number of subjects: 182
Study 17223212 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion at 2 ml/kg body weight per hour for 12 hours
Number of subjects: 889
Study 17223212 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 889
Study 15321001 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin via AERx iDMS
Number of subjects: 17
Study 15321001 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 17
Study 11478827 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free diet
Number of subjects: 12
Study 11478827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fibre (pea and inuline)
Number of subjects: 12
Study 11478827 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy polysaccharide fibre
Number of subjects: 12
Study 11478827 — intervention group
Group type: EXPERIMENTAL
Intervention: All three diets
Number of subjects: 12
Study 9544865 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 50
Study 9544865 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide-amiloride
Number of subjects: 50
Study 8112188 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 46
Study 8112188 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 46
Study 8112188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3170879 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrice (1100 ppm F)
Number of subjects: 10
Study 3170879 — intervention group
Group type: EXPERIMENTAL
Intervention: F dentifrice followed by F rinse (FD/FR)
Number of subjects: 10
Study 3170879 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals with gingival recession
Number of subjects: 10
Study 3170879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime F application
Number of subjects: 10
Study 3170879 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (8 ppm F)
Number of subjects: 10
Study 31518640 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA regulators
Number of subjects: 2
Study 31518640 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA MSTRG.1056.2
Number of subjects: 2
Study 31596802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal surgical-site injection (ropivacaine 200 mg, epinephrine 0.6 mg, and morphine 5 mg)
Number of subjects: 100
Study 31596802 — intervention group
Group type: COMPARATOR
Intervention: No injection (control)
Number of subjects: 100
Study 28329334 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + DSV + RBV for 12 weeks
Number of subjects: 22
Study 28329334 — intervention group
Group type: COMPARATOR
Intervention: DRV 800 mg QD
Number of subjects: 22
Study 28329334 — intervention group
Group type: COMPARATOR
Intervention: DRV 600 mg BID
Number of subjects: 22
Study 22831182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LF)
Number of subjects: 81
Study 22831182 — intervention group
Group type: COMPARATOR
Intervention: Low-Carbohydrate Diet (LC)
Number of subjects: 81
Study 21693045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 420
Study 21693045 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin and clavulanic acid
Number of subjects: 420
Study 21693045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 18043700 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin (MV) tablet
Number of subjects: 92
Study 16807277 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm-tip catheter
Number of subjects: 281
Study 16807277 — intervention group
Group type: COMPARATOR
Intervention: ecRFA catheter
Number of subjects: 281
Study 15476999 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme by a general practice assistant focusing on technical skills and coping with the disease
Number of subjects: 276
Study 15476999 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 276
Study 11238500 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 39
Study 11238500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9535242 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/ml vancomycin added to PN
Number of subjects: 38